Newronika Announces First Participant Implanted in ADVENT Pivotal Study

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Newronika-SpA

More Like This

PR Newswire associated0

Newronika Receives Investigational Device Exemption (IDE) from FDA to Initiate U.S. Clinical Trial of Adaptive DBS System

PR Newswire associated0

Newronika Receives CE Mark for αDBS®, Advancing Its Mission to Make Adaptive Therapy the Standard of Care

PR Newswire associated0

Newronika Receives CE Mark Approval for AlphaDBS, Advancing Adaptive Deep Brain Stimulation for Parkinson's Disease

PR Newswire associated0

Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform

PR Newswire associated0

Newronika Appoints Keith Carlton as Executive Chairman to Reinforce Strategic Leadership

PR Newswire associated0

Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia Completes Pilot Study and Announces Promising Initial Results

ONWARD Medical to Advance Parkinson’s Disease Pipeline with Support from The Michael J. Fox Foundation and US Department of Defense

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease